Therapix recently underwent an IPO on NASDAQ in the US of 2.3m ADS (worth $13.8m) to finance the clinical development of cannabinoid products. The lead clinical program, THX-TS01, is a combination of THC, the primary active ingredient in cannabis, and palmitoylethanolamide, a molecule generally regarded as safe, which is approved for use as a health supplement in some parts of Europe and Canada. THX-TS01 is currently in Phase II trials testing its potential for treating Tourette’s in adults. Therapix also has a preclinical program, dubbed THX-ULD01, seeking to treat mild cognitive impairment (MCI) using ultra-low dose THC, which is scheduled to begin Phase I trials in late Q217 or Q317. Both programs should qualify for a 505(b)(2) pathway to streamline their approval processes.
Written by
Therapix Biosciences |
Cannabinoids for underserved diseases
|
Pharma & biotech |
QuickView
7 June 2017 |
Share price graph
Share details
Business description
Bull
Bear
Analysts
Therapix Biosciences is a research client of Edison Investment Research Limited |
||||||||||||||||||||||||
Therapix recently underwent an IPO on NASDAQ in the US of 2.3m ADS (worth $13.8m) to finance the clinical development of cannabinoid products. The lead clinical program, THX-TS01, is a combination of THC, the primary active ingredient in cannabis, and palmitoylethanolamide, a molecule generally regarded as safe, which is approved for use as a health supplement in some parts of Europe and Canada. THX-TS01 is currently in Phase II trials testing its potential for treating Tourette’s in adults. Therapix also has a preclinical program, dubbed THX-ULD01, seeking to treat mild cognitive impairment (MCI) using ultra-low dose THC, which is scheduled to begin Phase I trials in late Q217 or Q317. Both programs should qualify for a 505(b)(2) pathway to streamline their approval processes.
THX-TS01: A potential Tourette’s treatment
According to the National Institute of Neurological Disorders and Stroke, 200,000 people in the US suffer from Tourette Syndrome, approximately one-third of whom are adults, which qualifies the program for an orphan drug designation from the FDA. THC has previously shown potential for movement disorders and independent pilot studies in Tourette’s have been promising. Therapix expects to complete the single-arm, open-label Phase IIa trials currently underway at Yale University in Q317. It also recently announced that an investigator sponsored Phase II placebo controlled crossover study would commence at Hannover Medical School in Q317.
THX-ULD01: Easing cognitive decline
MCI is a symptom cluster that can afflict patients with early Alzheimer’s disease, hypoxia or traumatic brain injury, among others. Therapix is investigating THX-ULD01 as a treatment primarily for MCI using an ultra-low dose of THC. Phase I results are expected in H217, which should enable initiation of a Phase II clinical study around the end of the year.
Valuation: Enterprise value of $12.4m
We calculate the enterprise value of Therapix at $12.4m (based on December 2016 filings indicating $727,440 year-end cash and estimated IPO net proceeds). The valuation may improve as Therapix’s drugs are entering historically underserved markets and the path to commercialisation is streamlined by seeking approval via a 505(b)(2) pathway. The company recently raised $13.8m in the public offering of ADSs on NASDAQ (2.3m at $6.00). It may require additional capital to bring its drugs to market, which may result in significant dilution, but the current cash level is expected to take THX-TS01 through Phase IIb and THX-ULD01 through Phase IIa.
|
Historical financials
Source: Company filings |
|
Disclaimer
|
|
Disclaimer
|
Research: Consumer
Following tough tomato campaigns in 2015 and 2016, La Doria management has delivered another quarter of results in line with expectations. The overarching strategy of shifting the production mix towards non-seasonal, value-added products with higher operating margins and lower volatility remains in place, and some recovery should come through from Q4 this year. The shares continue to trade at a significant P/E discount to their peers, and our DCF value of €12.49 (from €12.59) suggests 16% upside to the share price.